• Chemomab Therapeutics held its annual general shareholders meeting on May 5, 2026, following an adjournment from April 28, 2026.
• Shareholders backed re-appointment of Somekh Chaikin, a KPMG member firm, as independent registered public accounting firm for fiscal 2026.
• Authorization was granted to increase authorized share capital, including an amendment to articles of association to reflect the change; execution of the increase was not confirmed.
• Class II director appointments for Neil Cohen and Claude Nicaise were approved; seating of the directors was not confirmed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-002423), on May 06, 2026, and is solely responsible for the information contained therein.